News

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.

Even if survivors of pediatric neuroblastoma received treatment before 1 year old, they are still at risk for cognitive issues years later.

A study of patients with chronic lymphocytic leukemia looked into the role of treatment and disease itself in cognitive impairment.

Malnutrition is a potentially fatal adverse event that many patients undergoing treatment for cancer will face, but it's an adverse event that can be dealt with ahead of time during the first visit with an oncology nurse.

Here are the top 5 Oncology Nursing News stories for September 2019.

At the 2019 European Society for Medical Oncology, new study results showed promise for a frontline combination therapy for patients with newly diagnosed, advanced ovarian cancer.

After being diagnosed with essential thrombocythemia, former NHL referee Kerry Fraser did his best to maintain a positive attitude – and he says his oncology nurses played a huge role in that.

Atezolizumab, along with T-DM1, showed benefit for a subgroup of patients with breast cancer.

A phase III study found that adding 2 years of ovarian function suppression to tamoxifen extended disease-free survival in certain patients with hormone receptor-positive breast cancer.

Earlier today, the FDA approved daratumumab, in combination with other treatments, to treat patients with multiple myeloma that are eligible for autologous stem cell transplant.

Patients – and their caregivers too – should be key players in their multiple myeloma treatment planning.

While immunotherapy can be a life-saving approach for many patients with cancer, there are some cardiac adverse events that nurses should look out for.

Popular noninvasive colorectal cancer screening test, Cologuard, recently received permission from the FDA to expand its test.

Being an advocate might not only change your patients' lives but your life as well.

An expert discusses 2 new surgical treatments for breast cancer-associated lymphedema.

With the approval of 2 new JAK inhibitors for the management and treatment of myelofibrosis, the space is undergoing a new progression, with lots of questions left to answer.

A new study shows promising results for niraparib in the treatment of patients with ovarian cancer.

Sometimes, there's only so much you can do for patients in a clinical setting. But by sharing their stories and struggles, you can drive change that will affect their clinical treatment.

At the 2019 World Conference on Lung Cancer, an NSCLC expert weighed in on the usefulness of cell-free DNA-based testing versus traditional tissue testing for genomic sequencing.

The FDA has granted accelerated approval to the combination of lenvatinib and pembrolizumab in the treatment of patients with advanced endometrial carcinoma.

In 2019, 18,000 patients will die from metastatic urothelial cancer, but a new priority review recently granted to enfotumab vedotin shows promise for future treatment of patients with the disease.

In this episode of CURE Talks Cancer Podcast: Nursing Edition we speak with an oncology nursing expert on a topic not addressed enough, workplace violence.

Throughout all of the cancer landscape, there are racial disparities in the way patients are treated, and for mesothelioma patients, those disparities can make the difference between life and death.

Treating patients with HER2-positive metastatic breast cancer is difficult, and patients can fail multiple lines of direct treatment. But now, the FDA has accepted a supplemental new drug application for a combination treatment to help these patients failing multiple treatments.

In about 3% to 5% of patients with NSCLC MET alterations are presented that can drastically change a patient's prognosis. Now, an investigational MET inhibitor called tepotinib was granted a breakthrough designation by the FDA, and it may prove beneficial for patients in this space.